Flax Pond Capital LLC Invests $1.29 Million in Ultragenyx Pharmaceutical Inc. $RARE

Flax Pond Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 56,238 shares of the biopharmaceutical company’s stock, valued at approximately $1,293,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank increased its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares in the last quarter. Assetmark Inc. raised its position in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at $39,000. Aster Capital Management DIFC Ltd purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at $56,000. Finally, Smartleaf Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 43.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 751 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the sale, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the transaction, the director directly owned 27,951 shares in the company, valued at $702,129.12. This trade represents a 17.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 24,002 shares of company stock valued at $575,039. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

RARE has been the subject of a number of research reports. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. The Goldman Sachs Group lowered Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $61.00 to $25.00 in a research note on Tuesday, March 24th. Finally, Cantor Fitzgerald increased their target price on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $27.44 on Friday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $42.37. The stock’s fifty day moving average is $24.34 and its two-hundred day moving average is $24.88. The firm has a market capitalization of $2.70 billion, a P/E ratio of -4.49 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The business had revenue of $136.00 million for the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.Ultragenyx Pharmaceutical’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.57) EPS. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.